Chimeric: Media Thread, page-6

Brief Summary of presentation.

- Not uncommon to see T/O worth $10b and/or partnering at about $2B. In this area. JC has already been involved in two companies that have gone this way.
- Ph 1 - trial could take 2 years.
-preparing registration for ph2 trial
- will not require a PH3 clinical trial. Why? Glio has high unmet medical need. b. precedents have beens setup around the world based on PH 2 trails - MCL and MM approved based on single arm PH2 trails.
- Also looking at a basket trial for other cancers.
- Jc and management have been involved in of companies in cell therapy. Across the 4 people leading the organisation they have developed together over 25 cell therapies from preclinical through to FDA approval. And This team has worked on 4 out of 5 currently approved Car-T therapies available in the world. Let that sink it! There is massive experience here.
- Focus for 2021 -
a. PH1 and PH2 for CLTRX
b. developing pipeline.
C. continue to build team of expertise. Particular focus on hiring people with cell therapy expertise.

I have moved some funds to buy up in next few days. I am expecting a 2+ year time frame. This has the promise of a significant multi bagger over that period. Market cap at 60mil, imagine 2-3 Bill or more, do the math. But of course you need to be patient, it may take years.

DYOr and all that.